Publications

Publication Search

Search for publications by

National Working Group Meeting on ALK diagnostics in lung cancer

Abstract

The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.

Type Journal
ISBN 1743-7563 (Electronic) 1743-7555 (Linking)
Authors Cooper, W.; Fox, S.; O'Toole, S.; Morey, A.; Frances, G.; Pavlakis, N.; O'Byrne, K.; Dettrick, A.; Leong, T.; Rathi, V.; Spagnolo, D.; Hemmings, C.; Singh, M.; Moffat, D.; Tsao, M. S.; Wilner, K.; Buller, R.; Pitman Lowenthal, S.; Arifeen, S.; Binko, J.; Alam, M.;
Garvan Authors Prof Sandra O'Toole
Publisher Name Asia-Pacific journal of clinical oncology
Published Date 2014-01-01 00:00:00
Published Volume 10 Suppl 2
Published Pages 11-7
URL http://www.ncbi.nlm.nih.gov/pubmed/24673736
Status Published In-print
OpenAccess Link https://publications.gimr.garvan.org.au/download.php?12650_13074/2014-Cooper-Asia Pac J Clin Oncol.pdf